2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Published: mayo 08, 2024
normal heart compared to HCM heart diagram
  • Reaffirmed: This 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline has been reviewed and determined to be current as of May 2025. See the 2025 AHA/ACC Methodology and Policies Manual (PDF) for information on reaffirmation.
  • Hypertrophic Cardiomyopathy (HCM) remains a common genetic heart disease in populations throughout the world.
  • The prevalence of unexplained asymptomatic hypertrophy in young adults in the United States has been reported at about 1:500. Symptomatic hypertrophy based on medical claims data has been estimated at <1:3000 adults in the United States.
 
Read the full article in Circulation »

Video: 2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Writing Committee Chair Steve R. Ommen, MD, FACC, FAHA and Vice Chair Carolyn Ho, MD, FAHA discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. Following FDA approval of the first cardiac myosin inhibitor mavacamten for symptomatic obstructive HCM, the guideline now includes it as an option before more invasive therapies when first-line treatments like beta blockers or calcium channel blockers are not effective. Additionally, changes in recommendations regarding exercise and activity levels are discussed, emphasizing a more inclusive approach towards physical activity for patients with HCM.

Supporting Materials

Slide Sets

 

Related Resources